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Abstract
Background: Sunitinib is a protein tyrosine kinase-inhibitor targeting VEGFR, c-kit and PDGFR. It
has been approved for the treatment of metastatic renal-cell carcinoma and gastrointestinal
stromal tumors. Although it has been shown to prolong disease-free and overall survival in renal-
cell carcinoma patients, only 70% of the treated population receive a clinical benefit (CB) from the
treatment. Markers that could predict clinical benefit to sunitinib would be an important aid in
monitoring and following their treatment. We assessed the outcome and plasma proangiogenic
factors in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib in our
institution.
Methods: We have treated 42 patients with metastatic clear-cell renal carcinoma with sunitinib.
Plasma concentrations of VEGF-A, sVEGFR2 and PDGF were determined by ELISA.
Results: At the time of analysis 39 patients were evaluable for response and 30 patients had
obtained a clinical benefit (CB). Median progression-free survival was 268 days (8.93 months) and
median overall survival was 487 days (16.23 months). Interestingly, disease stabilization or objective
response resulted in comparable overall survival. Most treatment-related adverse events were of
mild-to-moderate intensity with one treatment-related death. Plasma sVEGFR2 and PDGF levels
had no predictive value. Fold-increase in plasma VEGF was significantly lower in patients that
obtained a CB as compared to patients that progressed after two cycles of treatment. Plasma VEGF
did not increase in patients with initial CB at the time of progression.
Conclusion: Sunitinib showed substantial activity in mRCC. Disease stabilization or objective
response resulted in comparable overall survival and both outcomes should be considered positive.
Fold-increase in plasma VEGF predicts for CB and could be a candidate marker. Progression after
initial CB is not associated with elevated plasma VEGF, implying a different mechanism of resistance.
Published: 12 March 2009
BMC Cancer 2009, 9:82 doi:10.1186/1471-2407-9-82
Received: 8 October 2008
Accepted: 12 March 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/82
© 2009 Kontovinis et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:82 http://www.biomedcentral.com/1471-2407/9/82
Page 2 of 10
(page number not for citation purposes)
Background
Clear-type renal cell carcinoma (RCC) represents 3% of all
new cancer cases, 85% of all renal cancers and by far the
most lethal urologic cancer. In 2008 it is estimated that
there will be 54,390 new kidney and renal pelvis cancer
cases (the majority of which are RCC) with a male to
female ratio of 1.56:1 [1]. Renal cell carcinoma occurs
more often in individuals aged 50 – 70 years old and it has
been associated with several risk factors such as smoking,
obesity and hypertension, although smoking probably is
the most significant risk factor [2]. Renal cell carcinoma
has been extremely resistant to chemotherapy, with disap-
pointing response rates (around 6%) [3]. The only effec-
tive treatment until recently was immunotherapy with
interferon-α and interleukin-2 with higher response rates
around 10–15% [4,5].
The majority of RCC occurs sporadically but there is a
small percentage of 1 – 4% that appears to carry a genetic
predisposition [6]. Both sporadic and inherited clear type
RCC is strongly associated with mutations in Von Hippel
Lindau (VHL) tumor suppressor gene [7]. VHL gene is
located on chromosome 3 and has a key role in the
hypoxia inducible pathway, inducing hypoxia inducible
factor (HIF-1 alpha and beta [8]) ubiquitinosis in the
presence of oxygen. HIF-1α is stable in hypoxia, but in the
presence of oxygen it is targeted for proteasomal degrada-
tion by the ubiquitination complex VHL [9]. HIF is a tran-
scriptional complex that mediates the response of human
cells to hypoxic environment resulting in the transcription
of genes as vascular endothelial growth factor (VEGF),
platelet-derived growth factor (PDGF), transforming
growth factor-α (TGF-α) and erythropoietin [10]. Platelet
derived growth factor receptors (PDGFRs) and vascular
endothelial growth factor receptors (VEGFRs) play an
essential role in tumor angiogenesis and growth [11]. VHL
– HIF-1 – VEGF pathway is therefore deregulated in RCC
and it represents a reasonable therapeutic target for renal
cell carcinoma [12].
Sunitinib malate (SUTENT®, SU11248; Pfizer Inc; New
York, USA) is an oral multitargeted tyrosine kinase inhib-
itor of VEGFR-1, VEGFR-2, Fms-like tyrosine kinase recep-
tor 3 (FLT3), c-KIT (stem-cell factor [SCF] receptor) and
PDGFR [13,14]. Phase I trials established the safety of 50
mg/day sunitinib (4 weeks on, 2 weeks off) and showed
responses in a variety of tumors including RCC and gas-
trointestinal stromal tumors (GIST) [15]. Phase II trials in
cytokine-resistant RCC showed a remarkable efficacy with
a disease control rate of 65% and a median time-to-pro-
gression of 8.7 months [16]. A large randomized phase III
trial comparing sunitinib to interferon-α resulted in statis-
tically significant higher objective response rates (31% vs.
6%, P < 0.001) and a longer progression-free survival (11
vs. 5 months), with a hazard ratio of 0.42 (0.32 to 0.54, P
< 0.001) [17]. Sunitinib is already approved for the treat-
ment of metastatic RCC and GIST and clinical trials are
ongoing in other indications as well as in the adjuvant
RCC treatment.
The majority of sunitinib-treated patients obtain a clinical
benefit in the form of either objective response or disease
stabilization (31% and 48% respectively in the phase III
trial). Furthermore there are patients who obtain a clinical
benefit that do not show a response in the beginning of
treatment and respond later in the course of treatment
(unpublished observation). It is therefore important to
recognize this population as RECIST criteria seem to be of
less value [18,19] and PFS is not directly related to
response rates, at least in the case of targeted treatments
[20]. Soluble forms of pro-angiogenic growth factors such
as VEGF-A and receptor sVEGFR2 or PlGF can be meas-
ured in the plasma of patients by ELISA and used as surro-
gate markers for response [21]. In the case of sunitinib
treatment for metastatic RCC it has been shown that
plasma VEGF levels increase after treatment and the ratio
of post-treatment VEGF to the pre-treatment levels is dif-
ferent in patients that respond vs. patients with stable dis-
ease or disease progression [22].
We have evaluated 42 patients with metastatic clear-type
renal cell carcinoma that were treated in our department
with sunitinib (between June 2006 and August 2008) and
their plasma levels of proangiogenic markers. There was a
different pattern of VEGF level responses in patients with
sunitinib-refractory disease (patients who experienced a
disease progression after the first two cycles of treatment)
and patients with sunitinib resistance (patients who orig-
inally obtained a clinical benefit and later progressed
while on treatment). This may have implications in the
treatment of these two different patient groups.
Methods
Eligibility criteria
Patients with metastatic clear type RCC, an Eastern Coop-
erative Oncology Group performance status ≤ 3 and age ≤
75. Patients could be enrolled either as first line metastatic
or second line after failure of cytokine treatment. All
patients had an appropriate renal (Cr ≤ 2), liver (transam-
inases ≤ 3 times the maximum limit of normal values,
total bilirubin ≤ 2 times the max limit of normal values)
and bone marrow function (Hb ≥ 10.0, WBC ≥ 3000, NEU
≥ 1000, and platelets ≥ 100,000). Patients had not severe
cardiologic disease and were required to have a recent
echocardiogram with left ventricular ejection fraction at
least 50%. In patients with a LVEF around 50% a MUGA
test was performed.
The study was approved by the "Theagenion" Cancer Hos-
pital ethics review board and was undertaken in accord-BMC Cancer 2009, 9:82 http://www.biomedcentral.com/1471-2407/9/82
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ance with the Declaration of Helsinki and Good Clinical
Practice Guidelines. All patients were informed on their
participation in this trial and signed the appropriate con-
sent form.
Drug administration
Sunitinib was administrated in the usual scheme (four
weeks on treatment, followed by two weeks off treatment,
on a six – week cycle). Starting dose was 50 mg daily and
in case of intolerance there was a dose reduction to 37.5
mg daily. No further dose reduction was needed in the
study.
Examinations on treatment
Physical examination, ECOG performance status, CBC
with differential and platelet count, complete biochemi-
cal profile at every scheduled visit on day 0, 15, 30, 45, 60,
75, 90 and at the beginning and the end of every subse-
quent treatment cycle. Thyroid function was accessed peri-
odically. Toxicity was evaluated using National Cancer
Institute Common Toxicity Criteria version 3.0. Primary
and metastatic disease was assessed either by computed
tomography scan or magnetic resonance imaging scan
before starting the treatment and at the end of every two
cycles (three months on treatment). RECIST criteria were
used for response evaluation [23].
Bioanalytics
Blood samples (15 ml) were collected from every patient
and centrifuged (1500 rpm for 5 minutes) to separate
plasma; aliquots were stored at -80°C and thawed only
once or twice. Plasma concentration of VEGF-A, PDGF-AB
and soluble VEGFR-2 were determined by enzyme-linked
immunosorbent assay (ELISA) according to the manufac-
turer's instructions (R & D Systems).
Post-sunitinib treatment
Patients who progressed on sunitinib and had a perform-
ance status at least 2, were treated with second (or third)
line sorafenib. One patient that progressed on sorafenib
but still remained in an eligible performance status is cur-
rently treated with temsirolimus.
Data analysis
Protein plasma concentration data and correlations with
response were analyzed with Microsoft Excel. Compari-
son results from Student's t-test with a p less than 0.05
were considered statistically significant. Kaplan-Meyer
and log-rank tests were performed using GraphPad Prism
5 for Windows.
Results
Patient Characteristics
We have examined 42 patients with clear-cell metastatic
carcinoma (31 men and 11 women) that received 50 mg
of sunitinib daily for 30 out of 45 days per cycle (median
age 64, range 25 – 75). Sunitinib was given either as first
line treatment (n = 29) or as second line after failure of
IFN-α (n = 13). Survival data were obtained from 40
patients. All patient characteristics are summarized in
tables 1 and 2.
Response to treatment (table 3)
From the 42 patients that were enrolled in the study 39
were evaluable for response at the time of analysis; 30
patients (77% in evaluable patients and 71% in the inten-
tion-to-treat [ITT] population) had a clinical benefit
(remission or disease stabilization). One patient received
less than two cycles because he developed a severe reac-
tion to sunitinib and he was switched to sorafenib and
another died from pulmonary embolism (reported as
severe adverse event) at cycle 2. From the 30 patients that
had a clinical benefit, 19 patients (49% in evaluable
patients and 45% in the ITT population) had a partial
response to treatment whilst 11 (28% in evaluable
patients and 26% in the ITT population) of them
obtained a disease stabilization. Nine patients (23% in
evaluable patients and 21% in the ITT population) had
Table 1: Patient characteristics
Patient characteristics %
Number
Total included 42 100
Assessable for response 39 93
Sex
Male 31 74
Female 11 26
Age (years)
Median 64
Range 25–75
Performance status
01 8 4 3
11 7 4 1
27 1 7
MSKCC risk classification
Favorable 3 7
Intermediate 23 55
Poor 16 38
Previous treatments
Nephrectomy 35 83
Interferon-α 13 31
Interferon-α + chemotherapy 6 14
Radiotherapy 14* 33
* Radiotherapy was directed against the primary tumor bed (as 
"adjuvant") in three patients; the rest (11 patients) received 
radiotherapy to the metastatic site (bone)BMC Cancer 2009, 9:82 http://www.biomedcentral.com/1471-2407/9/82
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disease progression and treatment was discontinued. The
42 patients that were enrolled in our study received an
average of 6 cycles of sunitinib (range 1 – 13). Two
patients experienced disease flare up during the off-treat-
ment periods and continued a non stop treatment with
37.5 mg of sunitinib daily.
Median progression free survival was 268 days (Kaplan –
Meyer, 95%, CI: 195 – 342 days) whereas median overall
survival was 487 days (95% CI, 236 – 738 days) (figure 1).
Overall survival was longer in patients that obtained a
clinical benefit than in patients that exhibited a disease
progression on first evaluation, after two cycles of
sunitinib treatment (763 vs. 178 days, p < 0.0001, log-
rank test). Interestingly, there was not any difference in
overall survival between patients that showed disease sta-
bilization or objective response on first evaluation (p =
0.6883, log-rank test, figure 2).
Adverse events
Most important adverse events are summarized in table 4;
the majority of them were grade 1 or 2. Most frequent
event was fatigue that appeared in 24 patients (57%) and
usually from day 15 until day 30 of each cycle. Although
it was a symptom that impeded most of the patients to
work regularly, it was almost fully reversible during the off
treatment period.
Hypertension (any grade) was presented in 19 patients
(45%), usually during the first two cycles of treatment and
it was treated successfully with common antihypertensive
medications. There was not any correlation between
hypertension and response, progression-free survival or
overall survival (data not shown). Seven patients devel-
oped grade 3 hypertension (required more than one drug
for control of blood pressure).
Hematological toxicity presented in 7 patients (17%) with
neutropenia, thrombocytopenia and anemia in 3 (7%), 5
(12%) and 4 (10%) patients respectively. Anemia was
treated with erythropoietin-B whilst neutropenia resolved
spontaneously and did not require treatment. There was
only one event of pancytopenia (grade 4 febrile neutrope-
nia, grade 3 thrombocytopenia and grade 3 anemia) after
only two weeks of treatment. Sunitinib was discontinued
and the patient went on to receive sorafenib with a stabi-
lization of disease for 9 months.
Skin toxicity with yellow skin discoloration appeared in
25 patients (60%), while six (14%) of them developed
additionally hand and foot syndrome with painful bul-
lous lesions. Mucositis (principally stomatitis) was fre-
quently reported (50%), as well as facial edema (21%)
which was mostly located around the eyelids. There was
one patient who presented with a generalized body edema
and was hospitalized until resolution. She refused further
treatment with sunitinib and was treated with sorafenib.
Other less frequent but equally important adverse events
were anorexia (29%), taste changes (52%), nausea/vomit-
ing (33%), epigastralgia (36%), diarrhea (26%) and thy-
roid function abnormalities (12%).
We observed only one fatal adverse event on a patient
who underwent a massive pulmonary embolism. The
patient had no history of deep vein thrombosis or other
hypercoagulative disease.
A seventy years old woman developed a spontaneous
pneumotorax proved to be provoked by remission of sub-
pleural metastatic foci. She was surgically treated and
sunitinib was continued until disease progression.
Table 2: Sites of relapse or metastasis
Site Number %
Local relapse 5 12
Bone* 17 41
Liver 4 10
Lung 34 81
Lymph nodes 8 19
Brain 1 2
Other sites 3 7
25 patients (60%) with at least 2 metastatic sites
* All patients with metastatic bone disease received bisphosphonate 
treatment (ibadronate or zoledronate). Eleven patients needed 
radiotherapy to the metastatic bone disease and three required an 
operation as well.
Table 3: Objective responses after two cycles of treatment in all evaluable patients (n = 39) and in the intention-to-treat population (n 
= 42).
Response Number %
(evaluable pts)
%
(ITT)
Total number of evaluable patients 39
Objective responses 19 49 45
Complete response 0 0 0
Partial response 19 49 45
Disease stabilization 11 28 26
Disease progression 9 23 21BMC Cancer 2009, 9:82 http://www.biomedcentral.com/1471-2407/9/82
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Three patients missed one cycle of treatment due to a LVEF
reduction without symptoms or signs of heart failure. The
minimum observed LVEF was 30%. Normal cardiac func-
tion was restored after a temporary break of treatment.
Plasma angiogenesis markers
Evaluation of clinical response was performed every two
cycles of treatment and evaluation of plasma biomarkers
was performed every 15 days for the first 2 cycles, then at
beginning and end of treatment cycles subsequently.
Although all time points were analyzed, we present the
data for the beginning and the end of each cycle (days 0
and 30, 45 and 75, etc). The plasma levels of all markers
in the middle of each cycle (e.g. day 15) in general fol-
lowed the trend between the start and the end of the cycle.
The number of patients that started each cycle is 39,
Progression-free (PFS) and overall survival (OS) of metastatic RCC patients treated with sunitinib Figure 1
Progression-free (PFS) and overall survival (OS) of metastatic RCC patients treated with sunitinib. Dotted lines 
represent confidence intervals. Median PFS = 268 days (8.9 months, 95% CI: 195 to 342 days) and median OS = 487 days (16.2 
months, 95% CI, 236 to 738 days).
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Overall survival by type of response on first evaluation (after  2 cycles of sunitinib treatment) Figure 2
Overall survival by type of response on first evalua-
tion (after 2 cycles of sunitinib treatment). Median OS 
for patients with progressive disease (PD) = 178 days (n = 9), 
for stable disease (SD) = 657 days (n = 11) and for partial 
response (PR) = 763 (n = 19). There is no statistical differ-
ence between SD and PR patients (p = 0.6883 with log-rank 
test) but there was a statistical significant difference between 
the PD and PR group (p < 0.0001, log-rank test) or between 
the PD and SD group (p = 0.0008).
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Table 4: Adverse events
Adverse event Any grade % Grade 3 %
Yellow skin discoloration 25 59 - -
Fatigue 24 57 1 2
Taste changes 22 52 - -
Mucositits 21 50 0 0
H y p e r t e n s i o n 1 9 4 571 7
Epigastralgia 15 36 0 0
Nausea/vomiting 14 33 0 0
Anorexia 12 29 2 7
Diarrhea 11 26 0 0
Facial edema 9 21 1 2
Hand and foot syndrome 6 14 0 0
Thyroid function abnormalities 5 12 0 0
Thrombopenia 5 12 1 2
Anemia 4 10 1 2
LVEF reduction* 3 7 1 2
Myalgia 3 7 0 0
Neutropenia 3 7 1 2
Constipation 2 7 0 0
Pneumothorax 1 2 1 2
Hemoptysis 2 7 0 0
There was one grade 5 adverse event (a patient who developed a 
massive pulmonary embolism, see text).
* Any grade: Reductions in LVEF more than 15% from baseline or 
LVEF less than 50%. Grade 3: 30–40%.BMC Cancer 2009, 9:82 http://www.biomedcentral.com/1471-2407/9/82
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(cycles 1 and 2), 29 (cycle 3), 28 (cycle 4), 25 (cycle 5) and
23 (cycle 6). Baseline levels of all markers are presented
on additional file 1.
For a better analysis patients were grouped according to
disease response after the first two cycles. A "clinical ben-
efit" group included both responders and patients that
achieved disease stabilization whereas patients in the
other group experienced progression of the disease.
Baseline sVEGFR-2 levels were comparable in both groups
at all time points. sVEGFR2 was decreased during
sunitinib treatment and increased during the off-treat-
ment periods at a similar manner as at has been observed
by other groups as well (figure 3).
Treatment with sunitinib lowered plasma PDGF levels in
both subgroups. Baseline plasma PDGF was lower in the
clinical benefit group (mean 16 ng/ml vs. 25 ng/ml, p =
0.15) and remained lower throughout the whole treat-
ment period. However this was never statistical significant
nor could have a predictive value. PDGF levels displayed
a similar fluctuation during treatment cycles as sVEGFR-2
(figure 4).
Baseline plasma VEGF-A levels were almost identical in
the clinical benefit vs. the non responders group (290 and
270 pg/ml respectively). Sunitinib treatment increased
plasma VEGF-A in both groups (figure 5). However this
was much higher in the group of patients who experi-
enced a disease progression after the first two cycles of
treatment (mean fold increase of 6.7), compared to the
clinical benefit group (mean fold increase of 3.1, p =
0.033), resulting in significantly higher plasma VEGF-A
levels at the end of the first two cycles in the non respond-
ers group (109 ng/ml versus 54 ng/ml, p = 0.010). The
group of patients that had a higher than average fold
increase in plasma VEGF-A by the end of cycle 2, had a sta-
tistically significant lower progression-free survival com-
pared to patients with smaller increases in VEGF-A
(median PFS 134 vs. 367 days, p = 0.010, HR = 0.2 [95%
CI = 0.059–0.68], figure 6). At the time of progression
patients that initially obtained a clinical benefit from
sunitinib treatment did not increase plasma VEGF-A levels
(as patients in the progression group) (figure 7), meas-
ured at the end of the last treatment cycle.
Discussion
We have treated 42 metastatic renal cell carcinoma
patients with sunitinib 50 mg per day, 4 weeks on and two
weeks off. Our results are in concert with other reports,
showing comparable clinical benefit ratio and a similar
time to progression. In the phase II trial reported by
Motzer [16] sunitinib treatment resulted in a clinical ben-
efit for the majority of patients (67%) and a median time-
to-progression of 8.7 months. The larger, phase III trial
Plasma sVEGFR2 ratio to baseline in metastatic RCC patients treated with sunitinib Figure 3
Plasma sVEGFR2 ratio to baseline in metastatic RCC patients treated with sunitinib. Vertical error bars represent 
SEM. Days 0, 45, 90, 135, 180 and 225 represent the beginning of cycles 1, 2, 3, 4, 5 and 6, respectively.
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(sunitinib vs. interferon-alpha) exhibited a progression-
free survival of 11 months in the sunitinib arm [17]. We
report a progression-free survival of 8.9 months and an
overall survival of 16 months. An interesting observation
is that patients who obtained disease stabilization after
two cycles of treatment had the same PFS and OS with
patients that showed disease regression with the RECIST
criteria. This implies that the aim of treatment is not to
obtain an objective response but rather to achieve a clini-
cal benefit by inhibiting the progression of the disease.
Overall, sunitinib treatment was tolerated well with the
majority of patients reporting grade I-II side effects.
Fatigue and taste changes were the most common side
effects that impaired patients' quality of life. Taste changes
particularly appeared after several cycles of treatment and
persisted as a problem until discontinuation of sunitinib.
However there was not any significant weight loss in this
cohort of patients, even though some of them experienced
stomatitis and gastric discomfort as well. Hypertension
was a common problem, but contrary to what reported by
Rixe et al [24], it did not predict for treatment effectiveness
in our patients.
Plasma angiogenesis markers were evaluated in all
patients every two weeks of treatment during the first two
cycles and on the start and end of treatment cycles there-
after. Plasma sVEGFR-2 and PDGF levels fluctuated dur-
ing the treatment period at a similar fashion as have been
reported by other groups as well. However, there was not
any predictive value in either of these two markers.
Plasma VEGF-A levels increased after treatment and fluc-
tuated during the on-off treatment periods in a similar
way as observed by other groups. VEGF-A levels increased
at the end of cycle 2 and this was more prominent in
patients that had disease progression than in patients that
obtained a clinical benefit. DePrimo et al reported on 63
patients with metastatic RCC treated with sunitinib after
failure of first-line cytokine therapy. They showed an
increase in plasma VEGF which was more prominent in
the patients with a partial response (PR) than in the non-
PR group [22]. We have observed completely the oppo-
site, though analyzing the results based on a different
grouping of patients. Since disease stabilization is consid-
ered a positive outcome in patients treated with targeted
therapies, we grouped patients in two groups. Group 1
consisted of patients who obtained a clinical benefit
(complete response, partial response or stable disease)
and remained on treatment. Group 2 was formed from
patients with progressive disease (according to RECIST)
that discontinued treatment after two full cycles of
sunitinib. Patients with clinical benefit had a tendency to
increase VEGF-A levels at a much lower fold ratio than
Plasma PDGF levels in metastatic RCC patients treated with sunitinib (ratio to baseline values) Figure 4
Plasma PDGF levels in metastatic RCC patients treated with sunitinib (ratio to baseline values). Vertical error 
bars represent SEM. Days 0, 45, 90, 135, 180 and 225 represent the beginning of cycles 1, 2, 3, 4, 5 and 6, respectively.
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patients with disease progression. On the contrary, when
patients from the clinical benefit group experienced a sec-
ondary progression (resistance to treatment) they did not
increase plasma VEGF-A. This may imply a different
mechanism between primary (disease refractory to treat-
ment) and secondary resistance. We hypothesize that
patients with disease refractory to treatment may benefit
from an additional anti-VEGF treatment like Bevacizumab
[25] (though bevacizumab/sunitinib combination trials
have recently been halted due to cases of microangio-
pathic hemolytic anemia [26]). This may not be the case
for the secondary resistance where other factors may con-
tribute to sunitinib failure. On the other hand, sunitinib
has a substantial clinical activity after bevacizumab fail-
ure, implying a different mechanism of resistance [21].
Conclusion
In conclusion, sunitinib showed a substantial antimumor
activity in patients with metastatic renal cell carcinoma.
The toxicity profile was favorable, with a few severe
adverse events. Obtaining a clinical benefit, either with
disease stabilization or with reduction of tumor burden
resulted in comparable overall survival and both out-
comes should be considered positive. The fold-increase in
plasma VEGF levels predicted for clinical benefit and over-
all survival and could be a candidate marker if confirmed
in larger series. On the other hand, progression after ini-
tial clinical benefit from sunitinib was not associated with
elevated plasma VEGF levels, implying a different mecha-
nism of resistance.
Plasma VEGF-A levels in metastatic RCC patients treated with sunitinib (ratio to baseline values) Figure 5
Plasma VEGF-A levels in metastatic RCC patients treated with sunitinib (ratio to baseline values). Vertical error 
bars represent SEM. Days 0, 45, 90, 135, 180 and 225 represent the beginning of cycles 1, 2, 3, 4, 5 and 6, respectively.
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Progression-free survival by fold increase in plasma VEGF-A Figure 6
Progression-free survival by fold increase in plasma 
VEGF-A. Group A (n = 10): Patients that had lower than 
average fold increase of plasma VEGF-A at the end of cycle 2, 
Group B (n-14): Patients that had higher than average fold 
increase of plasma VEGF-A at the end of cycle 2. Median PFS 
= 134 vs. 367 days, p = 0.010 by log-rank test, HR = 0.2 (95% 
CI = 0.059–0.68).
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